AMERSA Talks

After you listen please complete SAMHSA’s required Training and Technical Assistance (TTA) GPRA Post-Event Form. This form will gather satisfaction with the event to help improve future episodes.Medications for opioid use disorder (MOUD) are life-saving, yet three-quarters of people who need them still can't access them. Pharmacists are uniquely positioned to expand treatment, especially in rural communities and those with the fewest treatment options. Working collaboratively or independently, they can improve access, timing, and patient choice for MOUD care, starting where patients and medications already are. This episode examines how pharmacy-based models are closing gaps in addiction care deserts, how pharmacists can strengthen interdisciplinary care teams, and why fair reimbursement for pharmacist services matters for sustaining care in the communities hit hardest by overdose.Timestamps:[00:00:00] Welcome and Meet the Guests [06:41:00] Training Pharmacist Clinicians [09:42:00] Collaborative Practice Agreements [15:31:00] Holistic Primary Care Model [19:22:00] Patient Success Stories [26:31:00] Policy Shifts Enabling Prescribing [32:39:00] State Policy Map Resource [36:34:00] Stigma and Gatekeeping Mindset [39:23:00] Community Pharmacy Workflow Hurdles [41:50:00] Future Vision for MOUD AccessLinksAMERSAPharmacy BridgeBuprenorphine Prescribing Requirements and LimitationsFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Learn more about this topic. Download the companion toolkit and register for the follow-up live workshop at https://amersa.org/project/episode-2-substance-use-coercion/Intimate partner violence is associated with a six-times higher risk of developing a substance use disorder, yet most behavioral health and recovery training programs do not address substance use coercion (the intersection of intimate partner violence and substance use) as a core competency. This episode explores substance use coercion—how it operates, why it creates barriers to safety and care, and how cross-sector collaboration can improve outcomes for survivors and their families. Listeners will learn how the evidence-supported Substance Use Coercion ECHO Toolkit strengthens provider skills, builds partnerships between domestic violence and substance use services, and addresses critical gaps in training, coordination, and survivor-centered practice.Timestamps:[00:00:00] Episode intro: Why opioid treatment must evolve for older adults[00:01:00] Host and guest introductions + episode framing[00:02:00] Key themes: defining substance use coercion and its impact[00:03:00] What is substance use coercion? Core definition[00:04:00] Real-world examples: how coercion blocks access to treatment[00:05:00] Prevalence data: how common substance use coercion is[00:06:00] High rates in treatment settings and link to IPV risk[00:07:00] Training gaps across behavioural health and DV sectors[00:09:00] Mismatch in care models: why traditional recovery approaches fall short[00:12:00] Cross-sector collaboration: why it’s critical for better careLinksAMERSASubstance Use Coercion Echo Toolkit, an Evidence-Supported Capacity Building Curriculum - NCDVTMHhttps://ncdvtmh.org/toolkit/substance-use-coercion-palm-card-for-practitioners-english-and-espanol/7 common practices in substance use disorder care that can hurt survivorsFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

After you listen please complete SAMHSA’s required Training and Technical Assistance (TTA) GPRA Post-Event Form. This form will gather satisfaction with the event to help improve future episodes.Kratom products have rapidly evolved from traditional plant forms into highly potent semi-synthetic compounds now widely available in retail settings. This shift has introduced new risks, including use disorder, severe withdrawal, and overdose, while outpacing clinical guidance. This episode examines how these newer compounds differ pharmacologically, why they are more dangerous, and how clinicians can recognize and respond to kratom-related complications. Listeners will gain practical strategies for identifying kratom use disorder, managing withdrawal, and having informed, non-stigmatizing conversations with patients as these products continue to emerge and change.Timestamps:[00:00:00] Podcast introduction and overview of the series[00:01:00] Introduction to synthetic kratom and emerging risks[00:02:00] Guest introductions and episode focus[00:03:00] Learning objectives and clinical goals[00:05:00] First clinical case of severe kratom-related withdrawal[00:06:00] Rise of more dangerous synthetic kratom products[00:07:00] Historical use of kratom vs modern synthetic variants[00:10:00] Potency differences and hidden risks in retail products[00:15:00] Treatment discussion and buprenorphine use begins[00:47:00] Key takeaways and clinical recommendationsLinksAMERSAThe Bridge Center / Network for Emergency Addiction Treatment (NEAT) Clinician Kratom Survey ResultsBridge/NEAT Clinician Kratom Survey AnalysisBridge/NEAT Clinician Surveys Sign up (for future surveys)Bridge Guide to Adjuncts/Comfort Meds (see PAGE 2)Kratom | National Institute on Drug Abuse (NIDA)Find us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Learn more about this topic. Download the companion toolkit and register for the follow-up live workshop at https://amersa.org/project/episode-1-delivering-age-friendly-care-for-older-adults-in-opioid-treatment-programs/.Older adults are one of the fastest-growing populations in opioid treatment programs, yet most programs were not designed to address the realities of aging—multimorbidity, mobility limitations, cognitive changes, and social isolation. This episode explores how opioid use disorder treatment must evolve to better support older adults and address fragmented care. Listeners will learn how to apply the geriatric 5Ms framework—What Matters Most, Medication, Mentation, Mobility, and Multicomplexity— in opioid treatment program settings, strengthen cross-system collaboration, and implement practical strategies that promote safety, dignity, and person-centered care. This episode addresses critical gaps in integrating geriatric principles into addiction treatment practice.Timestamps:[00:00:41] Episode framing: older adults are the fastest-growing population in opioid treatment programs[00:01:08] Why treatment must evolve for ageing-related needs, fragmented care, and age-insensitive systems[00:03:06] Learning objectives: challenges, the 5Ms framework, and practical age-friendly care strategies[00:04:11] Why older adults in OTPs are increasing, including Medicare coverage and accelerated ageing with OUD[00:05:08] Kathy on the realities of caring for older adults, especially mobility and inaccessible clinic spaces[00:07:34] Zoe on retention, treatment access barriers, and the strain of co-occurring conditions like cancer and dialysis[00:09:16] Care transitions emerge as a major risk point, especially hospital to skilled nursing to home[00:15:19] Introduction to the geriatric 5Ms: Mobility, Mentation, Medications, Multicomplexity, and What Matters Most[00:23:11] Practical solutions for mobility barriers: medical exceptions, family support, visiting nurses, and dosing flexibility[00:42:28] Closing takeaways: logistical barriers, integrated care, and using age-friendly strategies in OTP settingsLinksFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

SafeSpot Overdose Prevention Hotline provides free, 24/7 virtual spotting services to people who use drugs alone. Born out of the grassroots Never Use Alone Massachusetts line, SafeSpot has evolved into a nationally recognized program housed at Boston Medical Center. In this episode, host Dr. Ruchi Shah speaks with Kimber King and TJ Thompson about SafeSpot’s journey from a volunteer-run initiative to a fully funded overdose prevention organization. Together, they discuss the importance of lived experience, lessons learned from rapid growth, and how SafeSpot is saving lives while challenging stigma, health disparities, and overdose risk in both urban and rural communities.Learning ObjectivesIdentify the risks of using substances alone and how virtual spotting addresses these risks.Analyze how stigma, isolation, and health disparities contribute to overdose deaths.Apply strategies for integrating hotline models like SafeSpot into clinical and community settings, including rural areas.Demonstrate how to do a warm handoff to SafeSpot in a traditional healthcare settingHost & Guest BiosRuchi Shah, DO (she/her) is an Assistant Professor of Medicine in the Division of General Internal Medicine at Montefiore Medical Center & Albert Einstein College of Medicine. She is the medical director of the Wakefield Hospital Addiction Medicine Consult Service and also provides primary care, addiction medicine, and reproductive healthcare outpatient. Ruchi strives to turn her big feelings into meaningful change and is grateful for the privilege of partnering with and learning from PWUD in their care.Kimber King (she/her) is the Operations Coordinator for the SafeSpot Overdose Hotline, an innovative virtual “spotting” service based at Boston Medical Center. A drug war and overdose survivor, she brings both lived experience and leadership to her work supporting people who use drugs and expanding access to overdose prevention services. Kimber’s story was featured on This American Life (“The Call”), and today she channels her journey into building workforce capacity, training operators, and advocating for practical overdose prevention strategies that save lives. She is also pursuing a Community Health Worker Certificate at the Community College of Vermont, further grounding her commitment to community health and meaningful change.Tj Thompson (they/them) is the Safety Coordinator at SafeSpot OFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Medications methadone and buprenorphine – are the most effective treatments for opioid use disorder. Decades of evidence show that they treat acute withdrawal and cravings, improve quality of life, reduce risk for HIV and hepatitis C, reduce overdose, and reduce risk of drug-related and all-cause mortality. Yet in the US, fewer than 1 in 5 people with OUD accesses them.In the US, Methadone is regulated unlike any other medication, including methadone for pain. With a few exceptions, in ambulatory settings, methadone must be administered from an opioid treatment program – a highly regulated addiction treatment setting.This episode talks with two clinical innovators who are leading work to bring methadone into critical access points in the SUD care continuum – withdrawal management settings and the hospital.Learning ObjectivesDescribe the importance of utilizing methadone in withdrawal management settings and at hospital discharge.Provide practical guidance to develop processes to implement methadone administration/ dispensation via the 72h rule in non-OTP settings, drawing on experience from withdrawal management and hospital settings.Describe some potential challenges and examples of how to address them.Show what 72-hour methadone dispense has potential to achieve in withdrawal management and hospital settings.Host & Guest BiosDr. Honora Englander is founder and Principal Investigator of the Improving Addiction Care Team (IMPACT), a nationally recognized model for hospital-based addiction care that includes physicians, social workers, and peers with lived experience in recovery. Dr Englander's work is at the intersection of addiction, health system transformation, and public health.Dr. Mike Winer serves as the Medical Director of a withdrawal management center in Portland, Oregon, and is an Assistant Professor in the Section of Addiction Medicine at Oregon Health & Science University. His work focuses on clinical innovation aimed at breaking down barriers to substance use care.Emily Skogrand, PharmD, is a clinical pharmacist at Oregon Health and Science University in Portland, Oregon. She works with the inpatient Internal Medicine department and on the addiction consult service with a special interest in optimizing care for patients with substance use disorders.Timestamps:00:00:00 — Intro, sponsors, goals00:01:00Find us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

This episode explores the Addiction Care Team Nurse Liaison Program (ACTNLP), a program that equips hospital nurses with substance use disorder (SUD) training to reduce stigma and improve outcomes for patients with SUD. Developed within an urban safety-net hospital, the program includes didactics, precepting with addiction specialists, and community site visits. Participants become SUD champions, educators, and leaders on their units. Early outcomes show high program completion and addiction certification rates, strong curriculum relevance, and improved knowledge and engagement. ACTNLP is a feasible, scalable model to enhance nursing capacity to provide addiction care in hospital settings.Learning ObjectivesDescribe the core components of the ACTNL program training and the ACTNL role in clinical implementation on the unit.Identify key benefits of training nurses in evidence-based addiction care, including impacts on patient outcomes, interdisciplinary communication, and stigma reduction.Recognize the value of the ACTNL program in its efforts to enhance nursing addiction education.Identify barriers to implementing nurse-led addiction training programs and explore strategies to overcome them.Assess potential for adaptation in diverse healthcare settings.Host & Guest BiosKristin Wason, MSN, NP-C, CARN, is a Nurse Practitioner at Boston Medical Center and serves as the Director of the Grayken Addiction Nursing Fellowship, the first addiction fellowship program for registered nurses in the United States. Kristin has experience working in numerous addiction treatment settings and currently provides direct patient care as a member of BMC’s Behavior Response Team and as a methadone provider at HCRC Boston. Kristin has published in several peer reviewed journals and is first author of Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse. She has also co-authored and authored numerous guidelines to treat patients with substance use disorders in the outpatient setting.Kelly Brandon, MSN, RNC, CNS, IBCLC, CARN, works as a Perinatal Clinical Nurse Specialist at San Francisco General Hospital. Prior to her nursing work she was a counselor and program manager for a street outreach program in San Francisco. In her role as the Co-Director of the ACTNL program she aims to bring evidence-based, easy to access, compassionate care to all patients thFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

In this episode, host Dr. Tim Kummer is joined by Holly Drone, EMS Pharmacist, and Jackson Thiets, paramedic and buprenorphine advocate with the Hennepin EMS Bridge Program. Together, they share the journey of implementing a paramedic-driven buprenorphine protocol, the lessons learned from their first year, and how the program has evolved to include holistic post-overdose care. The conversation highlights barriers faced, culture shifts needed in EMS and ED settings, and how moving from judgment to empathy—and empathy to action—can transform care for patients with opioid use disorder.Learning ObjectivesDescribe the development and implementation of a paramedic-driven buprenorphine protocol in a large urban EMS system, including the clinical rationale, training structure, and system-level logistics.Identify common barriers to prehospital buprenorphine use—such as stigma, protocol hesitancy, and supply chain issues—and explore practical strategies for overcoming them through clinical leadership and team buy-in.Understand the role of interdisciplinary collaboration—between EMS, pharmacists, and peer support specialists—in creating a holistic, post-overdose care model like the Hennepin EMS Bridge Program.Recognize how EMS and Emergency Departments can move from judgment-based responses to compassionate, action-oriented care for patients with opioid use disorder, reframing naloxone-only approaches to include long-term treatment initiation.Host & Guest BiosHost- Dr. Tim Kummer is an Emergency Physician and EMS Medical Director at Hennepin Healthcare, where he leads several initiatives focused on addressing the opioid crisis. He founded the Hennepin Bridge Program, an innovative team that connects patients with opioid use disorder to treatment through ED consults, field buprenorphine inductions, and follow-up care. Dr. Kummer also helped launch one of the first prehospital buprenorphine programs in the country and serves on the National Association of EMS Physicians work group developing national guidance on EMS’s role in the opioid epidemic. His work is grounded in bringing care directly to patients—whether in the field, at home, or in the emergency department—and meeting them where they are on their journey to recovery.Holly Drone, PharmD, is a Clinical Pharmacist at Hennepin Healthcare and Hennepin EMS specializing in emergency medicine and prehospital emergency care. She supports a Find us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

This episode will focus on the outreach and support service efforts within MATTERS that address barriers to treatment for opioid use disorder. While MATTERS is widely recognized for its harm reduction efforts, this episode will dig deeper into the essential support structures that make treatment more accessible, which can enhance the likelihood of a successful connection once referrals are made.The episode will cover how the program uses emergency telemedicine, peer networks, and wraparound programs to address barriers such as lack of insurance, transportation, and stigma. Additionally, it will discuss how follow-up with individuals navigating treatment helps to inform decision-making when it comes to the services MATTERS offers and how they communicate and interact with providers and partnering organizationsLearning ObjectivesIdentify means of creating a tailored referral system that streamlines connection to addiction medicine after jail or hospitalization to reduce barriers for patients seeking medications for OUDDemonstrate the critical role of community health navigation in successful care linkageHost & Guest BiosDr. Elizabeth Abbs is a primary care addiction medicine provider in San Francisco. She cares for a complex cohort of patients who live in the Tenderloin neighborhood - many of whom use drugs. Her work at the San Francisco Department of Public Health focuses on reducing barriers to care for patients accessing medications for their substance use disorder, incentivizing harm reduction efforts, and improving safe (and compassionate) prescribing of controlled medications for chronic pain.Phil McNamara is the Outreach Manager at MATTERS Network. Leading a team of Regional Outreach Coordinators across NYS, connecting individuals to outpatient follow-up care and harm reduction resources. He has a background as an SUD Counselor specializing in MOUD at a Buffalo-based OTP, and as a Community Outreach Coordinator specializing in HCV Linkage and Harm Reduction. Phil is the founder of Buffalo Resilience a nonprofit providing meals and harm reduction supplies & training to underserved communities in WNY. He believes that a strong community can offer many different paths to recovery and is passionate about building strong community connections.Isabella Wilklow is the Support Services Coordinator at MATTERS, where she assists individuals seeking connection to treatment for opioid usFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

The Program for Education in Drugs and Alcohol for Latine (PEDAL) is an example of a partnership between community-based organizations and addiction medicine clinicians. In this episode the guest discuss their collaboration to co-develop a training program for promotores, also known as community health workers, to address unhealthy substance use in the Latine community, offering a model for building workforce capacity to address increasing rates of overdose amongst Latine in a culturally and linguistically informed approach.Learning ObjectivesDemonstrate how to develop a collaborative partnership with community-based organizations to build workforce capacity.Identify the factors for effective implementation of a curriculum for community health workers.Name a strength to building the capacity of community health workers to address substance use.Host & Guest BiosHost: Marlene Martin, MD, is an Associate Professor of Clinical Medicine at UCSF, Director of Addiction Initiatives for the Latinx Center of Excellence, a hospitalist at San Francisco General Hospital (SFGH), and Director of the Addiction Care Team (ACT) at SFGH. Drawn to medicine to address health inequities and social injustices, her interests lie in systems improvement and innovation with a focus on addiction, community partnerships, Latine health, and care transitions. Marlene is committed to transforming systems of care to improve health outcomes for marginalized communities and ensuring that addiction care is compassionate, accessible, and equitable. She co-leads the Program for Education on Drugs and Alcohol for Latine (PEDAL).Triveni DeFries, MD, MPH is a physician and Assistant Professor at the University of California, San Francisco and Core Faculty in the Institute of Global Health Sciences. She practices internal medicine and addiction medicine at San Francisco General Hospital. She is a clinician consultant on the Substance Use Warmline for the National Clinician Consultation Center. She co-leads the Program for Education on Drugs and Alcohol for Latine (PEDAL).Dairo Romero is an immigrant from Colombia with a lifelong passion for social justice, community empowerment, and equity for immigrant and Latino communities. He is Community Initiatives Manager at Mission Economic Development Agency in San Francisco, where he works to advocate for affordable housing in the Mission District. There, he supports families Find us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

This episode explores the "contagious" nature of stigma in substance use disorders (SUDs), revealing how shame and discrimination spread beyond the 45-50 million Americans with SUDs to affect an estimated 45-300 million family members. While stigma's impact on individuals with SUDs is well-documented, this conversation spotlights how families become "stigmatized by association," driving them "underground" and leading to isolation, delayed help-seeking, compromised mental health, strained relationships, and poorer recovery outcomes for the entire family system.Learning ObjectivesIdentify at least three ways stigma impacts family members of individuals with substance use disorders, including specific effects on mental/physical health, help-seeking behaviors, and family dynamics.Analyze how "stigma by association" creates unique barriers for families in accessing support and contributing to their loved one's change process.Apply evidence-based communication strategies to reduce stigma when interacting with families affected by substance use disorders in professional or community settings.Host & Guest BiosDr. Brandee Madden is an Assistant Professor at Vanderbilt University School of Nursing. She is an experienced nursing educator and psychiatric mental health nurse practitioner who has provided treatment for mental health and substance use disorders in the community for over 15 years. Her clinical expertise is in the treatment of tobacco use in individuals with mental health and substance use disorders.Dr. Jeff Foote is a psychologist and nationally-recognized clinical researcher with over 30 years of experience in evidence-based treatment for substance use disorders and trauma. He has been driving change in the field of addiction treatment as Co-President and CEO of CMC:Foundation for Change, Co-Founder of the Center for Motivation and Change and co-author of the award-winning books "Beyond Addiction: How Science and Kindness Help People Change" and "The Beyond Addiction Workbook for Family and Friends."Dr. Carrie Wilkens is a psychologist with over 20 years of experience in substance use, trauma treatment, and working with families of those struggling with substance use. She is the Co-Founder and President of the non-profit, CMC:Foundation for Change, and Co-Founder of the Center for Motivation and Change treatment network and the co-author of the award-winning books "Beyond AddiFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

In this episode, Teetotal Initiative will provide insight into an innovative and underexplored but critical component of recovery: the impact of social interaction on recovery capital ecosystems and prevention of return to use. Despite its importance, organizing substance-free events for the community as a recovery tool is underutilized, leaving a gap in day-to-day sober- and recovery-oriented quality of life. This episode highlights Teetotal Initiative’s unique, scalable model for sober-focused events, offering tangible ideas for complementing formal treatment with consistent, community-rooted programming that addresses return to use predictors, stigma, and supports long-term recovery success.Learning ObjectivesIdentify three features that differentiate Teetotal Initiative’s model from other recovery support programs, communities, or services.Describe two ways Teetotal Initiative’s programming is strengthening both the recovery community and the broader community.Explain how Teetotal Initiative’s model and programming are helping to challenge or reduce self-stigma and social stigma around recovery.Host & Guest BiosHolly Hagle, Ph.D., serves as the Chief Learning and Research Officer for the American Academy of Addiction Psychiatry. Her expertise lies in applying Screening, Brief Intervention, and Referral to Treatment (SBIRT), with a particular focus on youth and young adults. Dr. Hagle has developed curricula addressing Adolescent Co-occurring Disorders, implementing SBIRT in youth settings, and creating educational content for transitional age youth. With over twenty years of experience as an addiction health services educator and researcher, her work spans treatment, recovery, and prevention, integrating applied research and education.Jackie Slaugenhaupt is a nonprofit advocate and financial services professional with over 15 years of volunteer experience in nonprofit leadership and fundraising. She brings more than 25 years of experience in financial services and has held leadership roles at several Fortune 100 banks. A change and management expert with a specialty in data visualization, Jackie is also a person in recovery. Her lived experience informs her work as co-founder of Teetotal Initiative, a nonprofit focused on helping individuals sustain recovery through community and connection.Dr. Lauren Broyles serves as the Director of Creative Arts Programming for Teetotal IFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

In this episode, we dive into why language in client and patient records matters—and how it can shape care experiences. We explore practical ways to use non-stigmatizing language in health records and discuss the role of electronic health record (EHR) in shaping documentation. Who designs these systems, and how can they be improved? We also examine real-world case scenarios where stigmatizing notes have had lasting impacts on individuals. Whether you're a provider, policymaker, or advocate, this episode offers insight into making health records more respectful, equitable, and aligned with patient-centered care.Learning ObjectivesRecognize how the electronic health record (EHR) can negatively impact individuals.Implement changes to existing EHR systems to incorporate strength-based, person-first, and non-stigmatizing languageReflect on the importance of self-awareness when writing notes and consider the potential uses and impacts of those records.Host & Guest BiosSunny Kung, MD is the medical director of the Mass General Brigham Merrimack Valley Bridge Clinic in Haverhill, MA. She completed her addiction medicine fellowship at Massachusetts General Hospital and her internal medicine residency at Brigham and Women's Hospital in Boston, MA. She is a dedicated primary care and addiction medicine clinician who specializes in caring for people who use substances, those who are unhoused, immigrants, people with limited English proficiency, and other marginalized folks. As a staunch believer in harm reduction, she believes in allowing people to live their lives with dignity and safety.Michelle Kavouras is a highly credentialed leader in addiction counseling, recovery support, and harm reduction with nearly a decade of experience training professionals in evidence-based care. She serves on multiple boards and commissions, including the NAADAC National Certification Commission for Addiction Professionals and Sitka’s Health Needs and Human Services Commission, and co-chairs the Southeast Alaska Alcohol Alliance. A dedicated harm reduction advocate, she collaborates on patient-centered research and works to advance stigma-free, person-centered care.Dr. Nichole Nidey is a maternal-child health epidemiologist and assistant professor at the University of Iowa College of Public Health. Nidey founded the EMPOWER Project in 2019, which is a patient-centered collaborative of persons with lived expFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Redemption stories in recovery are often more harmful than helpful. We’ve all absorbed the War on Drugs narrative—but even well-intended stories about substance use often reinforce stigma. In this episode, Meghann Perry and Dr. Dani Snyder-Young explore how internalized shame shapes personal and public storytelling, influencing care access and policy. They discuss research and applied storytelling techniques that shift the dominant narrative, promoting dignity and inclusion for people with lived and living experience of substance use. By embracing strength-based storytelling, we can rewrite the script—reducing stigma, fostering resilience, and broadening pathways to well-being. Tune in to learn how you can help change the conversation around substance use to prioritize dignity for people who use and used drugs.Learning ObjectivesDescribe the mechanism of belonging as it relates to storytelling, stigma and social supportIdentify the binary effect of redemption stories in the dominant narrative of substance use and recovery in the United States and how that impacts care for individualsName and apply three characteristics of strength-based storytelling in their personal or professional roleHost & Guest BiosDr. Felipe Vasudevan completed an Internal Medicine & Addiction Medicine fellowship at NYU, and then ran a consult service at Woodhull Hospital in Brooklyn, NY before directing the Addiction Consult Service & Bridge Clinic at UCLA Hospital. His interests include reducing barriers to pharmacotherapy and addressing stigma in the hospital setting for people who use drugs and improving access and visibility to methadone and contingency management programs.Meghann Perry, CARC, RCPF, is a Keynote Speaker, Educator and Addiction Recovery Coach Professional who has spent the last decade working in peer support, recovery advocacy and program design. She is best known for two groundbreaking programs: Recovery Storytelling and Embodied Storytelling and delivers high-impact presentations on storytelling as a tool for healing and advocacy for highly stigmatized conditions for organizations like NIH, NAADAC, HRSA, Peer Recovery Center of Excellence, and the Hazelden Foundation. Meghann is a former drug user who passionately supports people across the full spectrum of substance use, harm reduction and recovery and leads a team of dedicated facilitators redefining education in the suFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

 In San Antonio, HIV is treated with love, not judgment—and it’s working. We will discuss how stigma: 1) contributes to HIV acquisition, 2) prevents people living with HIV from seeking and remaining in care, and 3) effective, evidence-based strategies for mitigating stigma. We will explore effective ways to reach, support, and treat individuals who use substances, who are at a high risk for acquiring HIV and, once acquired, falling out of care.Learning ObjectivesAnalyze root-causes of HIV stigma;Explain the intersectionality of HIV risks and SUD;Identify evidence-based strategies for treating individuals with SUD who are also PLWH or at-risk.Host & Guest BiosDr. Deepika Slawek is an HIV primary care and addiction medicine physician and researcher practicing in the Bronx, NY. She attended University of Texas at Austin as an undergraduate and Texas A&M for medical school and then completed her medical training in New York State. She has been working in the field of HIV and addiction for over a decade.Michele Durham is the 31 year CEO of BEAT AIDS, the largest, longest-lasting HIV/AIDS Services Organization in South Texas. She holds a Bachelors of Business Administration degree in accounting from Lamar University and a Master’s degree in psychological education from the University of Texas at San Antonio with an emphasis in guidance and counseling. She has been working in the field of substance use disorder as it intersects with HIV in the South for over 35 years.Cindi Salinas is a substance use disorder counselor in Texas. She is a graduate of Elmhurst College and the Institute of Chemical Dependency Studies. She has been working in the field of substance use disorder as a counselor for eight years and in direct care for four years. She also has unique insight as someone with lived experience.Timestamps:[00:45] The current state of HIV in South Texas[04:59] Historical failings that caused the HIV spike in the South[07:56] How stigma worsens both HIV and substance use[10:15] What Beat AIDS does differently—and why it works[13:59] The importance of trauma-informed care[17:45] Peer support and rapid-start medication explained[22:43] The community-led model that’s saving lives[28:54] Mobile testing and reaching the unreachable[33:41] The changing landscape of HIV and SUD care in theFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Addiction care in the ER isn’t just about patients—it’s about fixing medicine itself.Emergency Department Bridge Programs allow ED physicians to connect patients in the ED with comprehensive addiction care. While the benefits of bridge programs for patients with opioid use disorder are known, what’s less understood is how these programs affect the lives of the providers themselves. For a paper published in Academic Emergency Medicine last year, researchers interviewed providers about these programs and found that patients were not the only benefactors.Learning ObjectivesED bridge programs may require extra work, but this study demonstrates they make life for ED providers better.Much attention is paid to hard data and quantitative research, but qualitative studies can be persuasive as well.We all should acknowledge that people need to find meaning in their work and incentivize programs that generate that meaning.Host & Guest BiosDr. Jeffrey Bratberg studies the essential and emerging roles community pharmacists play regarding opioid overdose response, harm reduction, and opioid use disorder treatment. He advocates for pharmacists’ expanded roles in medication access, public health promotion, and policy change through research, practice, and teaching.Rachel Haroz MD is an emergency medicine, toxicology and addiction medicine physician in Camden, NJ focused on bringing innovative and low barrier access to care to vulnerable populations.Jessica Heil is a public health researcher specializing in addiction studies and health disparities. As Research Manager at Cooper University Health Care, she leads clinical research, supervises staff, and fosters community collaborations. She has extensive experience in opioid use disorder treatment and harm reduction, she is committed to advancing evidence-based healthcare interventions.Timestamps:[00:03] Why Bridge Programs Are About More Than Patients[04:55] The “Aha Moment” That Changed a Career[07:33] The Surprising Source of Provider Satisfaction[10:55] How They Got ER Docs to Open Up[13:42] From Skeptic to Advocate—A Doctor’s Journey[17:59] What Providers Really Feel About This Work[20:33] Why Addiction Is an Emergency[23:45] The Power of 15 Seconds of Empathy[25:51] What’s Next—Methadone and EMS Programs[29:30] The One Story That Find us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Turns out, the most powerful tool against addiction stigma might just be someone society once gave up on. Despite significant advancements in addiction treatment, stigma remains one of the greatest barriers to care for individuals struggling with substance use disorder (SUD). Among healthcare professionals, stigma can manifest in ways that impact patient outcomes, access to care, and overall recovery success. This episode will explore how leveraging peers—those with lived experience in recovery—can be a powerful tool in combating stigma in medical settings. We will discuss real-world applications of peer support, the latest statistics on stigma in healthcare, and actionable strategies for fostering a more compassionate approach to SUD treatment. Learning ObjectivesReview the reality of stigma and its impact on healthcareIdentify the role of peers in recovery and two major healthcare environmentsIdentify strategies for integrating peers into the workforceKey TakeawaysPeer support can dramatically reduce stigma in healthcare by humanizing the recovery journey and modeling successful outcomes.Stigma among healthcare providers often stems from bias, not lack of evidence, making peer training and integration critical.Successful integration of peers requires clear role definitions, workflow systems, and true cultural acceptance across healthcare teams.Timestamps[00:36] Why stigma is the biggest barrier to addiction treatment[03:55] Healthcare workers’ surprising views on MAT (medication-assisted treatment)[06:00] The personal cost of stigma: a real-life story[09:05] What is peer support and why it’s powerful[12:35] How peers dramatically increase treatment engagement[15:00] Peers working in emergency rooms: how it changes outcomes[18:45] Peers in primary care: building trust and continuity[22:15] Key steps to integrating peers into healthcare teams[26:40] Supervision and mentorship strategies for peer specialists[30:59] Lessons learned: how to really defeat stigma in healthcareLinksAMERSASubstance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US). Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health [Find us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We’ve been blaming Appalachia for a healthcare crisis it didn’t create. Addiction in Appalachia isn’t what you think. This episode unpacks the nuanced reality of substance use disorder in a region that’s been stereotyped, ignored, and misunderstood for too long. Through powerful stories and clear strategies, it reveals how healthcare professionals, community leaders, and people with lived experience are fighting against systemic stigma and rebuilding trust.Dr. Devin Oller, a primary care and addiction medicine physician at the University of Kentucky, and Kayla Strother, a certified advanced practice nurse specializing in adult geriatric primary care, join Kate Roberts to lay out the layered social, political, and economic drivers of treatment resistance in Appalachia. From language shifts and provider education to jail protocols and peer-led movements, this episode is a roadmap for changing care where it matters most.Learning ObjectivesReview a framework for exploring Appalachian patients’ beliefs and knowledge about SUDExamine patients’ experience within the larger narrative about SUD in Appalachian communitiesIdentify ways to address internalized stigma in healthcare settings and the communityKey TakeawaysStigma in Appalachia isn’t just social—it’s systemic, and it directly blocks access to treatment through regulation, perception, and fear.Positive portrayals and community-first approaches, like peer support and harm reduction, are transforming how addiction is treated.Federal policy shifts are not enough without local engagement and context-aware delivery of care.Timestamps:[02:59] History and media’s role in shaping Appalachian stigma[07:00] The SNL skit that encapsulates a harmful stereotype[10:55] What "Demon Copperhead" gets right about addiction[14:58] The real transportation problem in rural Kentucky[17:59] State regulations vs. patient needs[23:55] Misconceptions around "treating one drug for another"[27:00] Role of harm reduction and community orgs[31:00] Inside the Healing Communities Study[34:00] The impact of lived experience campaigns[42:55] Language changes that can change everythingLinksAMERSADemon Copperhead, by Barbara Kingsolverhttps://bookshop.org/p/books/demon-copperheaFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We don’t have a drug crisis—we have a policy crisis. In episode one, Allyson Pinkhover, MPH, CPhT, CHO and Dr. Joe Wright explore some of the ways that urban planning, zoning, policing, and the location of addiction services combine to create or enforce a geography of containment. In Boston, Wright argues, land prices and the politics of what another scholar describes as “complaint-oriented policing” led to a smaller and smaller area in which visible drug use and homelessness were tolerated, and services for people with substance use disorders were located. This kind of geography, variations of which can be seen in many cities and towns, can create both problems and opportunities for patients as well as complex challenges for substance use care and public health.Key TakeawaysUrban planning and zoning laws play a massive but overlooked role in shaping substance use patterns in cities.The concept of ‘Hamsterdams’ reveals how some cities create designated spaces for drug use without public acknowledgment.Effective policy solutions require looking beyond criminalization and understanding the root causes of addiction and containment.Timestamps:[00:00] Introduction – Setting the stage for the discussion on zoning, real estate, and drug containment zones[02:15] What are ‘Hamsterdams’? – Explaining the concept of drug containment zones[06:40] How zoning laws influence substance use – The hidden role of urban planning in drug policy[11:55] The connection between real estate and drug containment – How property values and urban design affect policy[17:20] Public policy decisions that shape urban drug landscapes – Examining the role of legislation[22:45] Why some neighborhoods become containment zones – The factors that push certain areas into this role[28:30] The ethical debate around containment policies – Who benefits and who suffers?[34:10] What actually works in harm reduction? – Examining successful policies from various cities[39:05] Lessons from cities that changed their approach – Case studies and alternative strategies[42:10] Final thoughts and solutions – Where do we go from here in policy and public health?LinksAMERSADr Joe WrightFind us online at amersa.org/amersa-podcast Frontiers in Substance Use & Stigma & Substance Use are sponsored by Provider’s Clinical Support System – Medication for Opioid Use Disorder (PCSS-MOUD). Learn more about PCSS-MOUD at pcssnow.org.Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.Substance Use Across the Lifespan and Innovation in Action are sponsored by the Opioid Response Network (ORN). Learn more about ORN at opioidresponsenetwork.org.Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.